Drug Patents owned by Abbvie
1. Drug name - ANDROGEL
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8729057 | ABBVIE | Testosterone gel and method of use |
Oct, 2026
(4 years from now) | |
| US8754070 | ABBVIE | Testosterone gel and method of use |
Oct, 2026
(4 years from now) | |
| US8466137 | ABBVIE | Testosterone gel and method of use |
Oct, 2026
(4 years from now) | |
| US8759329 | ABBVIE | Testosterone gel and method of use |
Oct, 2026
(4 years from now) | |
| US8486925 | ABBVIE | Testosterone gel and method of use |
Oct, 2026
(4 years from now) | |
| US8466136 | ABBVIE | Testosterone gel and method of use |
Oct, 2026
(4 years from now) | |
| US8466138 | ABBVIE | Testosterone gel and method of use |
Oct, 2026
(4 years from now) | |
| US8741881 | ABBVIE | Testosterone gel and method of use |
Oct, 2026
(4 years from now) | |
Drugs and Companies using TESTOSTERONE ingredient
Treatment: Testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone
Dosage: GEL, METERED;TRANSDERMAL; GEL;TRANSDERMAL
| Strength | Dosage | Availability |
|---|---|---|
| 1.62% (20.25MG/1.25GM ACTUATION) | GEL, METERED;TRANSDERMAL | Prescription |
| 1.62% (20.25MG/1.25GM PACKET) | GEL;TRANSDERMAL | Discontinued |
| 1.62% (40.5MG/2.5GM PACKET) | GEL;TRANSDERMAL | Discontinued |
2. Drug name - TRICOR
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7320802 | ABBVIE | Methods of treatment using nanoparticulate fenofibrate compositions |
Feb, 2023
(4 months from now) | |
| US7276249 | ABBVIE | Nanoparticulate fibrate formulations |
Feb, 2023
(4 months from now) | |
Drugs and Companies using FENOFIBRATE ingredient
Treatment: Adjunctive therapy to diet in adults to reduce ldl-c, triglycerides and apo b, and increase hdl-c in patients with primary hypercholesterolemia or mixed dyslipidemia (types iia, iib) and to treat hypertriglyceridemia (types iv, v)
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 48MG | TABLET;ORAL | Prescription |
| 145MG | TABLET;ORAL | Prescription |
3. Drug name - TRILIPIX
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7259186 | ABBVIE | Salts of fenofibric acid and pharmaceutical formulations thereof |
Jan, 2025
(2 years from now) | |
| CN101480384A | ABBVIE | Formulation Comprising Fenofibric Acid, A Physiologically Acceptable Salt Or Derivative Thereof |
Apr, 2012
(10 years ago) | |
| CN1726024A | ABBVIE | Comprising Fenofibric Acid, A Physiologically Acceptable Salt Or Derivative Preparation |
Dec, 2023
(1 year, 2 months from now) | |
| CN100473378C | ABBVIE | Comprising Fenofibric Acid, A Physiologically Acceptable Salt Or Derivative Preparation |
Dec, 2023
(1 year, 2 months from now) | |
| EP1572190A1 | ABBVIE | Formulation Comprising Fenofibric Acid, A Physiologically Acceptable Salt Or Derivative Thereof |
Dec, 2023
(1 year, 2 months from now) | |
| EP1572190B1 | ABBVIE | Formulation Comprising Fenofibric Acid, A Physiologically Acceptable Salt Or Derivative Thereof |
Dec, 2023
(1 year, 2 months from now) | |
Drugs and Companies using CHOLINE FENOFIBRATE ingredient
Treatment: NA
Dosage: CAPSULE, DELAYED RELEASE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 45MG FENOFIBRIC ACID | CAPSULE, DELAYED RELEASE;ORAL | Prescription |
| EQ 135MG FENOFIBRIC ACID | CAPSULE, DELAYED RELEASE;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.